Table 6 Costs distribution according to scenario 1 to 4 from the societal perspective
Unitary cost (US$) | Amount | Total (US$) | |
|---|---|---|---|
Scenario 1 | |||
Hexavalent (DTaP-IPV-HepB-Hib) vaccine | 19.80 | 997,877 | 19,757,965 |
Pentavalent (DTwP-Hib-HepB) vaccine | 2.85 | 966,933 | 2,754,539 |
Average IPV (1) + bOPV (3) = 3.6 + (0.32*3) = 4.5 | 1.14 | 966,933 | 1,102,304 |
Difference of schemes | 15.81 | 966,933 | 15,288,431 |
Additional costs of the simultaneous scheme | 8,838,805 | ||
Cost to society | 6,449,627 | ||
Scenario 2 | |||
Hexavalent (DTaP-IPV-HepB-Hib) vaccine | 19.80 | 997,877 | 19,757,965 |
Pentavalent (DTwP-Hib-HepB) vaccine | 2.85 | 966,933 | 2,754,539 |
IPV four doses- average = 3.60 | 3.6 | 966,933 | 3,480,959 |
Difference of schemes | 13.35 | 966,933 | 12,909,776 |
Additional costs of the simultaneous scheme | 8,838,805 | ||
Cost to society | 4,070,971 | ||
Scenario 3 | |||
Hexavalent (DTaP-IPV-HepB-Hib) vaccine | 19.80 | 997,877 | 19,757,965 |
Pentavalent (DTwP-Hib-HepB) vaccine | 2.85 | 966,933 | 2,754,539 |
IPV four-dose bottle plus syringe = 2.10 | 2.10 | 966,933 | 2,030,559 |
Difference of schemes | 14.85 | 966,933 | 14,360,176 |
Additional costs of the simultaneous scheme | 8,838,805 | ||
Cost to society | 5,521,371 | ||
Scenario 4 | |||
Hexavalent (DTaP-IPV-HepB-Hib) vaccine | 19.80 | 997,877 | 19,757,965 |
Pentavalent (DTwP-Hib-HepB) vaccine | 2.85 | 966,933 | 2,754,539 |
IPV four doses- pre-filled syringe = 5.10 | 5.10 | 966,933 | 4,931,358 |
Difference of schemes | 11.85 | 997,877 | 11,459,377 |
Additional costs of the simultaneous scheme | 8,838,805 | ||
Cost to society | 2,620,572 | ||